Etomoxir: Difference between revisions

Latest revision as of 06:35, 20 April 2023

high-resolution terminology - matching measurements at high-resolution

Etomoxir

Description

Etomoxir (Eto; 2[6(4-chlorophenoxy)hexyl]oxirane-2-carboxylate) is an irreversible inhibitor of carnitine palmitoyltransferase I (CPT-I) on the outer face of the mitochondrial inner membrane. Eto inhibits fatty acid oxidation by blocking the formation of acyl carnitines from long-chain fatty acids which require the carnitine shuttle for transport into mitochondria. In contrast to long-chain fatty acids, the transport of short- and medium-chain fatty acids is carnitine-independent.

Abbreviation: Eto

Application in HRR

Eto (Etomoxir): ((+)-Etomoxir sodium salt hydrate); Sigma Aldrich; E-1905; storage: 2-8 °C; M = 338.76 g·mol^-1

Caution: Store tightly sealed, protected from exposure to light. Acute toxicity (oral, dermal, inhalation). Dust mask or eyeshields, faceshields and gloves are recommended by the preparation.

Preparation of 10 mM stock solution (dissolved in H₂O): The commercially available white compound is soluble in water.

Weigh 5 mg etomoxir.
Add 1.476 mL dt H₂O.
Divide into 500 µL portions.
Store frozen at -20 °C.

MitoPedia topics: Inhibitor

Labels:

MitoPedia:FAT4BRAIN

@@ Line 1: / Line 1: @@
 {{MitoPedia
 |abbr=Eto
-|description='''Etomoxir''' (Eto; 2[6(4-chlorophenoxy)hexyl]oxirane-2-carboxylate) is an irreversible inhibitor of carnitine palmitoyltransferase-1 (CPT-1) on the outer face of the inner mitochondrial membrane. Eto inhibits the transport of the long-chain fatty acids from the cytosol into the mitochondrial matrix, thereby blocking the formation of acyl carnitines in the cytosol, leading finally to inhibition of the fatty acid oxidation. Of note, in contrast to long-chain fatty acids, the transport of short- and medium chain fatty acids is carnitine-independent. The commercially available white compound is soluble in water.
+|description='''Etomoxir''' (Eto; 2[6(4-chlorophenoxy)hexyl]oxirane-2-carboxylate) is an irreversible inhibitor of [[carnitine palmitoyltransferase I]] (CPT-I) on the outer face of the mitochondrial inner membrane. Eto inhibits [[fatty acid oxidation]] by blocking the formation of acyl carnitines from long-chain fatty acids which require the carnitine shuttle for transport into mitochondria. In contrast to long-chain fatty acids, the transport of short- and medium-chain fatty acids is carnitine-independent.
 |info=
 }}
+__TOC__
+[[File:Etomoxir structure.png|right|300px|File:Etomoxir structure]]
+== Application in [[HRR]] ==
+::: '''Eto (Etomoxir):''' ((+)-Etomoxir sodium salt hydrate); Sigma Aldrich; E-1905; storage: 2-8 °C; M = 338.76 g·mol<sup>-1</sup>
+:::: <span style="color:#8B008B">'''Caution:''' Store tightly sealed, protected from exposure to light. Acute toxicity (oral, dermal, inhalation).  Dust mask or eyeshields, faceshields and gloves are recommended by the preparation.</span>
+::::'''Preparation of 10 mM stock solution''' (dissolved in H<sub>2</sub>O): The commercially available white compound is soluble in water.
+::::# Weigh 5 mg etomoxir.
+::::# Add 1.476 mL dt H<sub>2</sub>O.
+::::# Divide into 500 µL portions.
+::::# Store frozen at -20 °C.
 {{MitoPedia topics
 |mitopedia topic=Inhibitor
 }}
-[[File:Etomoxir structure.png|right|300px|File:Etomoxir structure]]
+{{Labeling
-== Application in [[HRFR]] ==
+|additional=MitoPedia:FAT4BRAIN
-'''Eto (Etomoxir):''' ((+)-Etomoxir sodium salt hydrate); Sigma Aldrich; E-1905; storage: 2-8 °C; FW= 338.76
+}}
-'''Caution:''' Store tightly sealed, protected from exposure to light. Acute toxicity (oral, dermal, inhalation.  Dust mask or eyeshields, faceshields and gloves are recommended by the preparation.
-'''Preparation of ... mM  stock solution''' (dissolved in H<sub>2</sub>O):
-::1) Weigh ...